A group of people with antisepsi has developed a drug that they say is effective in treating antisepseas.
The group, called Antisepsie, has a small number of patients who have had a single episode of an acute infection that caused the immune system to become compromised, the AP reported.
Their symptoms include fever, cough, muscle aches and weakness, but they can also have mild seizures.
The drug has not yet been tested on humans.
In an article published in the New England Journal of Medicine on Monday, the group said their results were encouraging.
The patients they treat are suffering from a range of symptoms that are typical of people who are having a bout of acute infectious disease, the article said.
Antispsie is the result of a collaboration between the University of Rochester and the University at Buffalo.
Researchers said they are now studying whether the drug will work in people who do not have a history of an infection.
Antisesepsis was developed by a group of researchers led by Dr. Paul B. O’Connor of the University Hospitals of Manchester in England.
O`Connor has been working to develop antisesepses for a decade and has seen positive results in people with severe infections.
The drugs work by blocking the production of a protein called IgG.
People with an allergic reaction to IgG have difficulty producing antibodies, and this causes the body to produce antibodies to the protein.
People without an allergy are also sensitive to the drug and are unable to produce IgG antibodies, which can be passed on to other people.
O”Connor has also seen some success in people in whom the immune systems of both the brain and the immune cells involved in the production and destruction of antibodies in the body are compromised.
In this case, the immune response was impaired in people without an immune system disorder.
The antisespies have been shown to have similar effectiveness in people suffering from acute infectious diseases such as pneumonia, hepatitis C and HIV, the researchers wrote.
The new antisespenes are meant to work within the body and are currently being tested in people before being tested on people with the more common acute infection, the study noted.
They are also being tested for the possibility of use in people undergoing chemotherapy.